Continuing ECMO with no possible transition to recovery or transplant.

Competing Interests: AS reports research grants and lecture fees from CytoSorbents, lecture fees from AstraZeneca and Getinge, and travel support and consulting fees from ARTCLINE, all outside of the submitted work. All other authors declare no competing interests. This Comment developed from discussion with the ECMO Ethics Workgroup of the American Society for Bioethics and Humanities Clinical Ethics Consultation Affinity Group.